1Vanden BH, Engelen M, Rochette F. Antifungal agents of use in animal health-chemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther, 2003, 26:5～29.
2Lamb DC, Kelly DE, White TC, et al. The R467K amino acid substitution in Candida albicans sterol 14α-demethylase causes drug resistance through reduced affinity. J Antimicrob Agents Chemother, 2000, 44:63～67.
3Prasad R, Kapoor K. Multidrug resistance in yeast Candida. J Int Rev Cytol, 2004, 242:215～248.
4Niimi M, Niimi K, Takano Y, et al. Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J Antimicrob Agents Chemother, 2004, 54:999～1006.
5Nakamura K, Niimi M, Niimi K, et al. Functional expression of Candida albicans drug efflux pump cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. J Antimicrob Agents Chemother , 2001 , 45:3366 ～3374.
6Perea S, Lopez-Ribot JL, Kirkparick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans stains displaying high-lever fluconazole resistance isolated from human immunodeficiency virus-infected patients. J Antimicrob Agents Chemother, 2001, 45:2676～2684.
7Hope WW, Tabernero L, Denning DW, et al. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. J Antimicrob Agents Chemother, 2004, 48:4377～4386.
8Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. J Clin Infect Dis, 2002, 34:563～571.
9Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. J N Engl J Med, 2002, 346:225～234.
